- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14:09 | Yakira Capital Management Calls on Atrium Therapeutics to Launch Strategic Review, Curb Cash Spending and Explain Dilutive Financing | 101 | PR Newswire | Yakira urges Board to explore strategic alternatives before further cash burn and dilution erode shareholder value; questions decision to raise $50 million after... ► Artikel lesen | |
| ATRIUM THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Do | Cantor Fitzgerald reiterates Atrium Therapeutics stock Overweight | 2 | Investing.com | ||
| 08.10. | Atrium Therapeutics: Aktie legt nach 50-Millionen-Dollar-Finanzierung kräftig zu | 1 | Investing.com Deutsch | ||
| 08.10. | Atrium Therapeutics raises $50M in private placement | 15 | Seeking Alpha | ||
| 08.10. | Atrium Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.09. | Atrium Therapeutics auf Wells-Fargo-Konferenz: RNA-Vorstoß bei Herzerkrankungen gewinnt an Fahrt | 9 | Investing.com Deutsch | ||
| 13.08. | Atrium Therapeutics, Inc. GAAP EPS of -$1.18 beats by $0.24 | 4 | Seeking Alpha | ||
| 13.08. | Atrium Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 13.08. | Atrium Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.08. | Atrium Therapeutics Reports Second Quarter 2026 Financial Results | 320 | PR Newswire | -- IND clearance for ATR 1072 and launch of Corventis Phase 1/2 trial in PRKAG2 syndrome --
-- Achieved second milestone payment under global cardiovascular collaboration... ► Artikel lesen | |
| 13.08. | Atrium Therapeutics Earns $15M BMS Milestone | 6 | Contract Pharma | ||
| 20.07. | Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | 256 | PR Newswire | SAN DIEGO, July 20, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company") today announced it awarded inducement grants on July 20, 2026 under... ► Artikel lesen | |
| 14.07. | Atrium Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.07. | Atrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 Syndrome | 302 | PR Newswire | -- ATR 1072 is the company's first precision cardiology program to enter the clinic --
-- Corventis will be the first clinical trial for people living with PRKAG2... ► Artikel lesen | |
| 15.05. | Leerink startet Coverage für Atrium Therapeutics mit "Outperform" | 2 | Investing.com Deutsch | ||
| 15.05. | Leerink initiates Atrium Therapeutics stock with outperform rating | 1 | Investing.com | ||
| 15.05. | Atrium Therapeutics, Inc. reports Q1 results | 1 | Seeking Alpha | ||
| 14.05. | Atrium Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 14.05. | Atrium Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 14.05. | Atrium Therapeutics Reports First Quarter 2026 Financial Results | 705 | PR Newswire | SAN DIEGO, May 14, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium," "Atrium Therapeutics" or the "Company"), a biopharmaceutical company... ► Artikel lesen |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 26,700 | +1,75 % | Wer verdient, wenn Patente fallen? Das Milliardenrennen von Formycon, Fresenius und Pfizer! | Wenn der Patentschutz umsatzstarker Biopharmazeutika ausläuft, entsteht ein Milliardenmarkt für Nachfolgeprodukte. Michael Sen, der Unternehmenslenker des deutschen Gesundheitskonzerns Fresenius SE... ► Artikel lesen | |
| GILEAD SCIENCES | 138,24 | +1,22 % | BofA hebt Kursziel für Gilead Sciences nach positiven Studiendaten an | ||
| TEVA PHARMACEUTICAL INDUSTRIES | 41,350 | +0,15 % | Teva: Uvakitug Maintains Meaningful Efficacy Improvements In Long-term Extension Study | PETAH TIKVA (dpa-AFX) - Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries (TEVA), and Sanofi announced new positive data from the RELIEVE UCCD phase 2b long-term extension... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 456,15 | +1,89 % | Forget Cystic Fibrosis: Vertex's Next Growth Engine Could Be Hormone Disorders | ||
| VIATRIS | 16,526 | +1,49 % | 1,65 Milliarden Dollar für Schmerztherapien: Viatris kauft Biotech - während Mesoblast vor wichtigen Phase-III-Daten steht | ||
| EYEPOINT | 0,410 | +4,59 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 19.10.2026 | Folgende Wertpapiere werden in den Handel an der Frankfurter Wertpapierbörse (FWB) aufgenommen.
1. US88025U1097 10X GENOMICS INC
2. NL0000852564 AALBERTS NV
3. SE0016589188 ELECTROLUX AB
4. SE0000115446... ► Artikel lesen | |
| BAUSCH HEALTH | 5,575 | -1,33 % | Bausch Health Companies Inc: Bausch Health obtains wider PrOkedi drug coverage | ||
| IONIS PHARMACEUTICALS | 39,870 | +0,71 % | DelveInsight Business Research, LLP: Severe Hypertriglyceridemia Market Set for Growth During the Forecast Period (2026-2036) Following Approval of Ionis' TRYNGOLZA and Emergence of Novel Therapies | DelveInsight | Severe Hypertriglyceridemia Market Set for Growth During the Forecast Period (2026-2036) Following Approval of Ionis' TRYNGOLZA and Emergence of Novel Therapies | DelveInsight
The severe hypertriglyceridemia... ► Artikel lesen | |
| ASSEMBLY BIOSCIENCES | 18,300 | +1,67 % | Assembly Biosciences: Was die neuen Daten verraten | ||
| ALNYLAM PHARMACEUTICALS | 208,80 | +0,29 % | Alnylam Pharmaceuticals (ALNY) vs. IONS and ARWR: Can Pipeline Growth Restore Confidence After the Guidance Cut? | ||
| NEKTAR THERAPEUTICS | 32,760 | +0,18 % | Nektar Therapeutics: New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 2026 | Rezpegaldesleukindemonstrateddurabilityanddeepeningofresponsethroughone year of treatment in two dermatological indications, reinforcing the differentiated properties... ► Artikel lesen | |
| AMARIN | 9,950 | -3,40 % | Amarin Corporation plc: Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence | Q2 2026 Results Highlight Global Volume Growth, Lower Operating Expenses and Positive Cash Flow For Full Year 2026, Company Expects Continued Growth in International Markets, Maintenance of VASCEPA's... ► Artikel lesen | |
| FILANA THERAPEUTICS | 0,688 | +12,79 % | FILANA THERAPEUTICS, INC. - 8-K, Current Report | ||
| ORAMED PHARMACEUTICALS | 3,610 | 0,00 % | Oramed Pharmaceuticals Inc.: Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet | Significant Appreciation in Alpha Tau (NASDAQ: DRTS) Position (up ~$128 Million)
Scilex (NASDAQ: SCLX) Loan Substantially Repaid
Total Cash and Assets Build... ► Artikel lesen | |
| AXSOME THERAPEUTICS | 139,15 | +0,11 % | Bis zu 76 Prozent der Alzheimer-Patienten betroffen: Warum Axsome, Lundbeck, Suven und NeuroThera gegen Agitation vorgehen |
Das Unternehmen ATRIUM THERAPEUTICS INC kann der Branche Pharma zugeordnet werden. Der aktuelle Kurs liegt bei 8,210 Euro und damit +7,88 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ATRIUM THERAPEUTICS INC finden Sie auf Wallstreet Online.